HomeCompareVBIO vs EQR

VBIO vs EQR: Dividend Comparison 2026

VBIO yields 512.82% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VBIO wins by $74719.32M in total portfolio value
10 years
VBIO
VBIO
● Live price
512.82%
Share price
$0.39
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$74719.37M
Annual income
$54,003,807,702.14
Full VBIO calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — VBIO vs EQR

📍 VBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVBIOEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VBIO + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VBIO pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VBIO
Annual income on $10K today (after 15% tax)
$43,589.74/yr
After 10yr DRIP, annual income (after tax)
$45,903,236,546.82/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, VBIO beats the other by $45,903,231,892.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VBIO + EQR for your $10,000?

VBIO: 50%EQR: 50%
100% EQR50/50100% VBIO
Portfolio after 10yr
$37359.71M
Annual income
$27,001,906,588.87/yr
Blended yield
72.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

VBIO
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VBIO buys
0
EQR buys
0
No recent congressional trades found for VBIO or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVBIOEQR
Forward yield512.82%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$74719.37M$47.8K
Annual income after 10y$54,003,807,702.14$5,475.61
Total dividends collected$72929.43M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: VBIO vs EQR ($10,000, DRIP)

YearVBIO PortfolioVBIO Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$61,982$51,282.05$11,380$679.82+$50.6KVBIO
2$363,383$297,062.31$13,014$837.25+$350.4KVBIO
3$2,016,476$1,627,655.79$14,961$1,036.20+$2.00MVBIO
4$10,598,885$8,441,255.59$17,297$1,289.22+$10.58MVBIO
5$52,806,644$41,465,837.52$20,121$1,613.15+$52.79MVBIO
6$249,582,121$193,079,012.24$23,561$2,030.84+$249.56MVBIO
7$1,119,909,823$852,856,952.70$27,783$2,573.54+$1119.88MVBIO
8$4,774,834,551$3,576,531,040.71$33,013$3,284.39+$4774.80MVBIO
9$19,360,340,566$14,251,267,596.86$39,547$4,223.51+$19360.30MVBIO
10$74,719,372,108$54,003,807,702.14$47,791$5,475.61+$74719.32MVBIO

VBIO vs EQR: Complete Analysis 2026

VBIOStock

Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of inflammatory disorders in the United States. The company is developing tetrahydrocannabinol glycoside (VBX-100), an oral cannabinoid prodrug for inflammatory bowel disease and irritable bowel syndromes. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was founded in 2007 and is headquartered in Los Angeles, California.

Full VBIO Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this VBIO vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VBIO vs SCHDVBIO vs JEPIVBIO vs OVBIO vs KOVBIO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.